Conference Call with Max Financial Services Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Fortis Healthcare announced Q2FY26 results Consolidated Revenues at Rs 2,331 crore, up 17.3% YoY. Operating EBITDA Margin at 23.9% vs 21.9% in Q2FY25. Profit after Tax at Rs 329 crore, up 70.3% YoY. Hospital Business Revenues at Rs 1,974 crore, up 19.3% YoY. Operating EBITDA margin at 22.9% vs 21.4% in Q2FY25. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said: “We have maintained a healthy growth momentum across both our hospital and diagnostics businesses. In the hospital segment, key specialties such as Oncology and Renal Sciences grew by 29% and 22%, respectively, compared to the same period last year. Our growth and expansion strategy is accelerating on multiple fronts. The company recently entered into a lease agreement for a ~200-bedded multi-specialty hospital in Greater Noida, a facility that we had previously been managing under an O&M; arrangement. This expands our presence in Delhi NCR to ~2,100 beds. The integration of Gleneagles units under the O&M; arrangement with Fortis is progressing well and we have also made our foray in Lucknow with an O&M; arrangement for a 550 bedded super specialty hospital to be constructed by the Ekana Group.” “In the diagnostics business, we continue to witness a buoyant recovery in both revenue and EBITDA margin and expect this positive momentum to continue going forward.” Result PDF
Holding Companies company Bajaj Holdings & Investment announced Q2FY26 results BHIL's consolidated profit after tax increased to Rs 1,559 crore in Q2FY26 v/s Rs 1,436 crore in Q2FY25. BHIL's standalone profit after tax increased to Rs 2,181 crore in Q2FY26 v/s Rs 1,051 crore in Q2FY25 An interim dividend of Rs 65 per equity share (650%) was declared on 16 September 2025 and paid on 14 October 2025, amounting to Rs 723 crore. Result PDF